Physician profile

Christopher John Lashley

Internal Medicine · Charleston, SC

NPI 1982017778

$186.66

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$59.04

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Allergan, INC. $27.46 2019-2020
Ucb, INC. $22.90 2019
Lexicon Pharmaceuticals, INC. $21.95 2024
Abbvie INC. $19.63 2023
Novartis Pharmaceuticals Corporation $18.64 2020
E.R. Squibb & Sons, L.L.C. $17.46 2024 Eliquis
Melinta Therapeutics, LLC $16.90 2019
Janssen Pharmaceuticals, INC $15.03 2021
Novo Nordisk INC $14.15 2019
Merck Sharp & Dohme LLC $12.54 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Christopher John Lashley

$186.66

in general payments reported 2019-2025

Years
2019-2024
Top company
Allergan, INC.

https://glasscript.com/doctor/1159964/christopher-john-lashley

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.